Silencing ROR1 and ROR2 inhibits invasion and adhesion in an organotypic model of ovarian cancer metastasis

Oncotarget

Volumn 8, Issue 68, 2017, Pages 112727-112738

  Henry, Claire ^a   Hacker, Neville ^b   Ford, Caroline ^a  

^a UNIVERSITY OF NEW SOUTH WALES   (Australia)

^b ROYAL HOSPITAL FOR WOMEN   (Australia)

Author keywords

Epithelial ovarian cancer; Metastasis; Omentum; ROR1; ROR2

Indexed keywords

COLLAGEN; ROR1 PROTEIN; ROR2 PROTEIN; SHORT HAIRPIN RNA; UNCLASSIFIED DRUG; WNT PROTEIN;

ARTICLE; CANCER CELL CULTURE; CELL ADHESION; CELL CULTURE; CELL INVASION; CELL ISOLATION; CELL MIGRATION; CELL PROLIFERATION; COCULTURE; CONTROLLED STUDY; DRUG TARGETING; FEMALE; FIBROBLAST; GENE EXPRESSION; GENE OVEREXPRESSION; GENE SILENCING; HUMAN; HUMAN CELL; MESOTHELIUM CELL; METASTASIS; OMENTUM; OVARIAN CANCER CELL LINE; OVARY CARCINOMA; OVCA4 CELL LINE; PROTEIN FUNCTION; STROMA; UPREGULATION; WNT SIGNALING;

EID: 85038873810     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.22559     Document Type: Article

References (39)

1. Fidler IJ. The pathogenesis of cancer metastasis: the 'seed and soil' hypothesis revisited. Nat Rev Cancer. 2003; 3:453-58. https://doi.org/10.1038/nrc1098
2. Lengyel E. Ovarian cancer development and metastasis. Am J Pathol. 2010; 177:1053-64. https://doi.org/10.2353/ ajpath.2010.100105
3. Collins D, Hogan AM, O'Shea D, Winter DC. The omentum: anatomical, metabolic, and surgical aspects. J Gastrointest Surg. 2009; 13:1138-46. https://doi. org/10.1007/s11605-009-0855-1
4. Clark R, Krishnan V, Schoof M, Rodriguez I, Theriault B, Chekmareva M, Rinker-Schaeffer C. Milky spots promote ovarian cancer metastatic colonization of peritoneal adipose in experimental models. Am J Pathol. 2013; 183:576-91. https://doi.org/10.1016/j.ajpath.2013.04.023
5. Chien HP, Ueng SH, Chen SC, Chang YS, Lin YC, Lo YF, Chang HK, Chuang WY, Huang YT, Cheung YC, Shen SC, Hsueh C. Expression of ROR1 has prognostic significance in triple negative breast cancer. Virchows Arch. 2016; 468:589-95. https://doi.org/10.1007/s00428-016-1911-3
6. Debebe Z, Rathmell WK. Ror2 as a therapeutic target in cancer. Pharmacol Ther. 2015; 150:143-48. https://doi. org/10.1016/j.pharmthera.2015.01.010
7. Henry C, Llamosas E, Knipprath-Meszaros A, Schoetzau A, Obermann E, Fuenfschilling M, Caduff R, Fink D, Hacker N, Ward R, Heinzelmann-Schwarz V, Ford C. Targeting the ROR1 and ROR2 receptors in epithelial ovarian cancer inhibits cell migration and invasion. Oncotarget. 2015; 6:40310-26. https://doi.org/10.18632/ oncotarget.5643
8. Sun B, Ye X, Lin L, Shen M, Jiang T. Up-regulation of ROR2 is associated with unfavorable prognosis and tumor progression in cervical cancer. Int J Clin Exp Pathol. 2015; 8:856-61
9. Henry CE, Llamosas E, Djordjevic A, Hacker NF, Ford CE. Migration and invasion is inhibited by silencing ROR1 and ROR2 in chemoresistant ovarian cancer. Oncogenesis. 2016; 5:e226. https://doi.org/10.1038/oncsis.2016.32
10. Zhang H, Qiu J, Ye C, Yang D, Gao L, Su Y, Tang X, Xu N, Zhang D, Xiong L, Mao Y, Li F, Zhu J. ROR1 expression correlated with poor clinical outcome in human ovarian cancer. Sci Rep. 2014; 4:5811. https://doi.org/10.1038/ srep05811
11. Zhang S, Cui B, Lai H, Liu G, Ghia EM, Widhopf GF 2nd, Zhang Z, Wu CC, Chen L, Wu R, Schwab R, Carson DA, Kipps TJ. Ovarian cancer stem cells express ROR1, which can be targeted for anti-cancer-stem-cell therapy. Proc Natl Acad Sci USA. 2014; 111:17266-71. https://doi. org/10.1073/pnas.1419599111
12. Henry CE, Emmanuel C, Lambie N, Loo C, Kan B, Kennedy CJ, de Fazio A, Hacker NF, Ford CE. Distinct Patterns of Stromal and Tumor Expression of ROR1 and ROR2 in Histological Subtypes of Epithelial Ovarian Cancer. Transl Oncol. 2017; 10:346-56. https://doi. org/10.1016/j.tranon.2017.01.014
13. Domcke S, Sinha R, Levine DA, Sander C, Schultz N. Evaluating cell lines as tumour models by comparison of genomic profiles. Nat Commun. 2013; 4:2126. https://doi. org/10.1038/ncomms3126
14. Mitra AK, Davis DA, Tomar S, Roy L, Gurler H, Xie J, Lantvit DD, Cardenas H, Fang F, Liu Y, Loughran E, Yang J, Sharon Stack M, et al. In vivo tumor growth of high-grade serous ovarian cancer cell lines. Gynecol Oncol. 2015; 138:372-77. https://doi.org/10.1016/j.ygyno.2015.05.040
15. Ruiz PA, Jarai G, Collagen I. Collagen I induces discoidin domain receptor (DDR) 1 expression through DDR2 and a JAK2-ERK1/2-mediated mechanism in primary human lung fibroblasts. J Biol Chem. 2011; 286:12912-23. https:// doi.org/10.1074/jbc.M110.143693
16. Quan J, Yahata T, Adachi S, Yoshihara K, Tanaka K. Identification of receptor tyrosine kinase, discoidin domain receptor 1 (DDR1), as a potential biomarker for serous ovarian cancer. Int J Mol Sci. 2011; 12:971-82. https://doi. org/10.3390/ijms12020971
17. Dejmek J, Dib K, Jönsson M, Andersson T. Wnt-5a and G-protein signaling are required for collagen-induced DDR1 receptor activation and normal mammary cell adhesion. Int J Cancer. 2003; 103:344-51. https://doi. org/10.1002/ijc.10752
18. Jönsson M, Andersson T. Repression of Wnt-5a impairs DDR1 phosphorylation and modifies adhesion and migration of mammary cells. J Cell Sci. 2001; 114:2043-53
19. Akbarzadeh S, Wheldon LM, Sweet SM, Talma S, Mardakheh FK, Heath JK. The deleted in brachydactyly B domain of ROR2 is required for receptor activation by recruitment of Src. PLoS One. 2008; 3:e1873. https://doi. org/10.1371/journal.pone.0001873
20. Gentile A, Lazzari L, Benvenuti S, Trusolino L, Comoglio PM. The ROR1 pseudokinase diversifies signaling outputs in MET-addicted cancer cells. Int J Cancer. 2014; 135:2305-16. https://doi.org/10.1002/ijc.28879
21. Al-Alem LF, McCord LA, Southard RC, Kilgore MW, Curry TE Jr. Activation of the PKC pathway stimulates ovarian cancer cell proliferation, migration, and expression of MMP7 and MMP10. Biol Reprod. 2013; 89:73. https:// doi.org/10.1095/biolreprod.112.102327
22. Schummer M, Drescher C, Forrest R, Gough S, Thorpe J, Hellström I, Hellström KE, Urban N. Evaluation of ovarian cancer remission markers HE4, MMP7 and Mesothelin by comparison to the established marker CA125. Gynecol Oncol. 2012; 125:65-69. https://doi.org/10.1016/j. ygyno.2011.11.050
23. Song N, Liu H, Ma X, Zhang S. Placental growth factor promotes metastases of ovarian cancer through MiR-543-regulated MMP7. Cell Physiol Biochem. 2015; 37:1104-12. https://doi.org/10.1159/000430235
24. Bartakova A, Michalova K, Presl J, Vlasak P, Kostun J, Bouda J. CD44 as a cancer stem cell marker and its prognostic value in patients with ovarian carcinoma. J Obstet Gynaecol. 2017; 1-5:1-5. https://doi.org/10.1080/0 1443615.2017.1336753
25. Lin J, Ding D. The prognostic role of the cancer stem cell marker CD44 in ovarian cancer: a meta-analysis. Cancer Cell Int. 2017; 17:8. https://doi.org/10.1186/ s12935-016-0376-4
26. Tjhay F, Motohara T, Tayama S, Narantuya D, Fujimoto K, Guo J, Sakaguchi I, Honda R, Tashiro H, Katabuchi H. CD44 variant 6 is correlated with peritoneal dissemination and poor prognosis in patients with advanced epithelial ovarian cancer. Cancer Sci. 2015; 106:1421-28. https://doi. org/10.1111/cas.12765
27. Coticchia CM, Curatolo AS, Zurakowski D, Yang J, Daniels KE, Matulonis UA, Moses MA. Urinary MMP-2 and MMP-9 predict the presence of ovarian cancer in women with normal CA125 levels. Gynecol Oncol. 2011; 123:295-300. https://doi.org/10.1016/j.ygyno.2011.07.034
28. Kenny HA, Kaur S, Coussens LM, Lengyel E. The initial steps of ovarian cancer cell metastasis are mediated by MMP-2 cleavage of vitronectin and fibronectin. J Clin Invest. 2008; 118:1367-79. https://doi.org/10.1172/ JCI33775
29. Kenny HA, Lengyel E. MMP-2 functions as an early response protein in ovarian cancer metastasis. Cell Cycle. 2009; 8:683-88. https://doi.org/10.4161/cc.8.5.7703
30. Stadlmann S, Pollheimer J, Moser PL, Raggi A, Amberger A, Margreiter R, Offner FA, Mikuz G, Dirnhofer S, Moch H. Cytokine-regulated expression of collagenase-2 (MMP-8) is involved in the progression of ovarian cancer. Eur J Cancer. 2003; 39:2499-505. https://doi.org/10.1016/j. ejca.2003.08.011
31. Lee JM, Mhawech-Fauceglia P, Lee N, Parsanian LC, Lin YG, Gayther SA, Lawrenson K. A three-dimensional microenvironment alters protein expression and chemosensitivity of epithelial ovarian cancer cells in vitro. Lab Invest. 2013; 93:528-42. https://doi.org/10.1038/ labinvest.2013.41
32. Yu J, Chen L, Cui B, Widhopf GF 2nd, Shen Z, Wu R, Zhang L, Zhang S, Briggs SP, Kipps TJ. Wnt5a induces ROR1/ROR2 heterooligomerization to enhance leukemia chemotaxis and proliferation. J Clin Invest. 2015; 126:585-98. https://doi.org/10.1172/JCI83535
33. Huang J, Fan X, Wang X, Lu Y, Zhu H, Wang W, Zhang S, Wang Z. High ROR2 expression in tumor cells and stroma is correlated with poor prognosis in pancreatic ductal adenocarcinoma. Sci Rep. 2015; 5:12991. https:// doi.org/10.1038/srep12991
34. Chen CW, Lin NY, Zhang Y, Huang J, Palumbo-Zerr K, Schambony A, Beyer C, Schett G, Distler JH. SAT0185 Wnt5a Promotes Fibroblast Activation and Tissue Fibrosis by ROR2/ RYK Dependent Activation of PCPSignaling. Ann Rheum Dis. 2016; 75:735.2-735. https:// doi.org/10.1136/annrheumdis-2016-eular.3466
35. Igota S, Tosa M, Murakami M, Egawa S, Shimizu H, Hyakusoku H, Ghazizadeh M. Identification and characterization of Wnt signaling pathway in keloid pathogenesis. Int J Med Sci. 2013; 10:344-54. https://doi. org/10.7150/ijms.5349
36. Freedman RS, Deavers M, Liu J, Wang E. Peritoneal inflammation-A microenvironment for Epithelial Ovarian Cancer (EOC). J Transl Med. 2004; 2:23. https://doi. org/10.1186/1479-5876-2-23
37. Batista L, Gruosso T, Mechta-Grigoriou F. Ovarian cancer emerging subtypes: role of oxidative stress and fibrosis in tumour development and response to treatment. Int J Biochem Cell Biol. 2013; 45:1092-98. https://doi. org/10.1016/j.biocel.2013.03.001
38. Peters PN, Schryver EM, Lengyel E, Kenny H. Modeling the Early Steps of Ovarian Cancer Dissemination in an Organotypic Culture of the Human Peritoneal Cavity. J Vis Exp. 2015; e53541:e53541. https://doi.org/10.3791/53541
39. Gebäck T, Schulz MM, Koumoutsakos P, Detmar M. TScratch: a novel and simple software tool for automated analysis of monolayer wound healing assays. Biotechniques. 2009; 46:265-74. https://doi.org/10.2144/000113083